aTYR PHARMA (ATYR) Other Accumulated Expenses (2014 - 2025)

aTYR PHARMA (ATYR) has reported Other Accumulated Expenses for 12 consecutive years, with $844000.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Other Accumulated Expenses rose 9.75% year-over-year to $844000.0; the trailing twelve-month figure through Dec 2025 stood at $844000.0 (up 9.75% YoY), and the FY2025 full-year result was $844000.0, up 9.75% from the prior year.
• Other Accumulated Expenses climbed to $844000.0 in Q4 2025 per ATYR's latest filing, from $769000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $1.9 million in Q4 2022 and bottomed at $672000.0 in Q4 2021.
• Historically, Other Accumulated Expenses has averaged $1.1 million across 5 years, with a median of $844000.0 in 2025.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses jumped 187.2% in 2022, then tumbled 43.01% in 2023.
• Over 5 years, Other Accumulated Expenses stood at $672000.0 in 2021, then soared by 187.2% to $1.9 million in 2022, then sank by 43.01% to $1.1 million in 2023, then slumped by 30.09% to $769000.0 in 2024, then grew by 9.75% to $844000.0 in 2025.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $844000.0, $769000.0, and $1.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.